Skip to main content
Premium Trial:

Request an Annual Quote

Genosity Inks Deal With Gemini Therapeutics to Develop Assay for AMD Clinical Trial Patient Selection

NEW YORK — Genosity said on Wednesday that it has signed an agreement to develop a molecular diagnostic for use in selecting patients for a clinical trial of a dry age-related macular degeneration (AMD) drug candidate under development by Gemini Therapeutics.

Gemini's drug, called GEM103, is designed for dry AMD in patients with disease-associated complement factor H (CFH) loss-of-function gene variants.

Under the terms of its agreement with Gemini, Genosity will use samples from prospective clinical study participants to create a custom next-generation sequencing panel that can identify individuals with these CFH variants. Genosity will then validate the assay and use it to help Gemini select patients suitable for enrollment in a Phase IIa study of GEM103.

Additional terms were not disclosed.

"Gemini is a leader in leveraging molecular information to develop precision therapeutics in AMD and we are excited to expand our testing menu to support another partner's need to have a unique biomarker test available for trial support," Genosity Cofounder and President Robert Daber said in a statement.

In early 2020, Genosity partnered with Columbia University to sequence samples of patients with wild-type cardiac amyloidosis to identify potential disease-causing genes and pathways. In August, the Iselin, New Jersey-based company received CLIA approval for a liquid biopsy assay for cancer monitoring and residual disease detection in biopharmaceutical research and clinical trials.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.